
adjust ep exclud non-cash one-tim item
headquart wilmington de biotechnolog compani develop drug treat cancer
autoimmun diseas baricitinib jak inhibitor test treatment rheumatoid arthriti ra
commerci right entitl royalti sale drug
april fda host advisori committe adcom meet baricitinib initi reject
april panel support approv vote approv
safeti concern remain result surpris given safeti concern phiii-
imbal thromboembol blood clot event placebo numer event
statist signific despit demonstr superior efficaci refractori ra
patient like target popul real world use well superior head-to-head studi humira
test believ advers event ae rate sever enough lead reject dose
resubmiss propos recommend dose patient inadequ respons
compar recommend certain patient origin submiss
approv phiii patient move week treatment result
suffici data long-term safeti howev panel vote favor due
robust efficaci gener lower ae rate includ blood clot believ panel vote
increas chanc approv increas estim possibl success
given conserv tone fda present
commerci impact baricitinib alreadi approv eu japan
recommend dose taper need gener sale approv
germani major use actual believ differenti bari xeljanz
sale emerg competitor run phiii addit indic
atop dermat three dose test
what left valu jakafi iclusig per share estim
per share valu inci royalti baricitinib fda like make decis bari next
month potenti becom valu play depend stock move post fda decis
uncertainti remov believ could attract takeout target novarti
celgen host investor event june continu recommend hold stay
sidelin fda decis bari pmv estim per share
million except per share
exclud non-cash one-tim item beyond
million except per share
current market discount pmv
after-tax payment buy option convert holder privat market valu
jing research analyst prepar report herebi certifi view express report accur reflect analyst
person view subject compani secur research analyst receiv direct
indirect compens express specif recommend view report
